Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Lewerenz V, Ruzicka T. Scleredema adultorum associated with type 2 diabetes mellitus: a report of three cases. J Eur Acad Dermatol Venereol. 2007 Apr;21(4):560-1. https://doi.org/10.1111/j.1468-3083.2006.01959.x.
Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum. 2006 Jun;35(6):355-9. https://doi.org/10.1016/j.semarthrit.2006.01.004.
Manchanda Y, Das S, Sharma VK, Srivastava DN. Scleredema associated with carcinoma of the gall bladder. Br J Dermatol. 2005 Jun;152(6):1373-4. https://doi.org/10.1111/j.1365-2133.2005.06631.x.
Miyagawa S, Dohi K, Tsuruta S, Shirai T. Scleredema of Buschke associated with rheumatoid arthritis and Sjögren's syndrome. Br J Dermatol. 1989 Oct;121(4):517-20. https://doi.org/10.1111/j.1365-2133.1989.tb15522.x.
Alves J, Judas T, Ferreira T, Matos D, Bártolo E. Scleredema associated with Sjögren's syndrome. An Bras Dermatol. 2015 May-Jun;90(3 Suppl 1):81-3. https://doi.org/10.1590/abd1806-4841.20153779.
Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016 Jul 7;2:16047. https://doi.org/10.1038/nrdp.2016.47.
Solans-Laqué R, López-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum. 2011 Dec;41(3):415-23. https://doi.org/10.1016/j.semarthrit.2011.04.006.
Golovach IYu, Yehudina YeD. Prognostic markers of lymphoma in primary Sjogren’s syndrome. Practical oncology. 2019;2(3):9-23. https://doi.org/10.22141/2663-32126.96.36.1999.186472.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al; EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020 Jan;79(1):3-18. https://doi.org/10.1136/annrheumdis-2019-216114.
Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X. Primary Sjogren syndrome. BMJ. 2012 Jun 14;344:e3821. https://doi.org/10.1136/bmj.e3821.
Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum. 2004 Apr;50(4):1262-9. https://doi.org/10.1002/art.20176.
Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005 Nov 14;165(20):2337-44. https://doi.org/10.1001/archinte.165.20.2337.
Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. Medicine (Baltimore). 2016 Jun;95(25):e3766. https://doi.org/10.1097/md.0000000000003766.
Zhang W, Feng S, Yan S, et al. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford). 2010 Mar;49(3):571-7. https://doi.org/10.1093/rheumatology/kep404.